Mediastinal Lymphadenopathy in Non-small Cell Lung Cancer: Prognostic Value of PET/CT
https://doi.org/10.33667/2078-5631-2019-2-17(392)-23-26
Abstract
Positron emission tomography combined with computer tomography (PET/CT) is considered as a noninvasive method for evaluation in lung cancer. SUVmax provides information on biological aggressiveness, key pathological features and potential of tumor spread. However, standardized and generally accepted criteria for determining malignant and benign lymph nodes do not exist, which is a common problem for molecular diagnostics physicians and generates clinical demand, since the standardization of these criteria has the potential to improve diagnostic accuracy, comparability between research and a general understanding by clinicians. To this end, we tried to determine the diagnostic accuracy of the maximum standardized absorption value (SUVmax) for mediastinal lymph nodes, compare the ability to predict mediastinal malignancy: SUVmax, the ratio of SUVmax l node to SUVmax of the primary tumor (SUVmaxN/SUVmaxT), and also SUVmaxN/SUVmaxT multiplied by maximum tumor diameter (SUV index).
About the Authors
N. A. Ognerubov
Tambov State University n. a. G. R. Derzhavin
Russian Federation
Russian Federation
Tambov
T. S. Antipova
PET-Technology Cо., Centre for Nuclear Medicine
Russian Federation
Russian Federation
Tambov
References
1. Состояние онкологической помощи населению России в 2016 году. Под ред. А. Д. Каприна, В. В. Старинского, Г. В. Петровой — М.: МНИОИ им. П. А. Герцена — филиал ФГБУ «НМИРЦ» Минздрава России, 2017. — илл. — 236 с.
2. Methods for Staging Non-small Cell Lung Cancer: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
3. Quint LE, Francis IR, Wahl RL, Gross BH, Glazer GM. Preoperative staging of non-small cell carcinoma of the lung: imaging methods. AJR Am J Roentgenol. 1995;164:1349–59.
4. Kyoichi Kaira et al. Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer
5. Cuaron J, Dunphy M, Rimner A. Role of FDG-PET scans in staging, response assessment, and follow-up care for non-small cell lung cancer. Front Oncol. 2013;2:208.
6. Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J, Goldstraw P, et al. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 2009;4(7):792–801
7. Hellwig D, Baum RP, Kirsch C. FDG-PET, PET/CT and conventional nuclear medicine procedures in the evaluation of lung cancer: a systematic review. Nuklearmedizin. 2009;48(2):59–69
8. Taus Á, Aguiló R, Curull V, Suárez-Piñera M, Rodríguez-Fuster A, Rodríguez de Dios N, et al. Impact of 18F-FDG PET/CT in the treatment of patients with non-small cell lung cancer. Arch Bronconeumol. 2014;50(3):99–104.
9. Shiraki N, Hara M, Ogino H et al. False-positive and true-negative hilar and mediastinal lymph nodes on FDG-PET — radiological-pathological correlation. Ann Nucl Med 2004; 18: 23–8
10. Chao F, Zhang H. PET/CT in the Staging of the Non-Small-Cell Lung Cancer. J Biomed Biotechnol. 2012;2012:783739.
11. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2:706–14.
12. Li X, Zhang H, Xing L, Ma H, Xie P, Zhang L, et al. Mediastinal lymph nodes staging by (18) F-FDG PET/CT for early stage non-small cell lung cancer: A multicenter study. Radiother Oncol. 2012;102:246–50.
13. Lv YL, Yuan DM, Wang K, Miao XH, Qian Q, Wei SZ, et al. Diagnostic performance of integrated positron emission tomography/computed tomography for mediastinal lymph node staging in non-small cell lung cancer: A bivariate systematic review and meta-analysis. J Thorac Oncol. 2011;6:1350–8.
14. Hu M, Han A, Xing L, Yang W, Fu Z, Huang C, et al. Value of dual-time-point FDG PET/CT for mediastinal nodal staging in non-small-cell lung cancer patients with lung comorbidity. Clin Nucl Med. 2011;36:429–33.
15. Eschmann SM, Friedel G, Paulsen F, et al. For staging of advanced non-small cell lung cancer prior to neoadjuvant radiochemotherapy. Eur J Nucl Med Mol Imaging. 2002;29:804–8.
16. Seltzer MA, Yap CS, Silverman DH, Meta J, Schiepers C, Phelps ME, et al. The impact of PET on the management of lung cancer: The referring physician’s perspective. J Nucl Med. 2002;43:752–6
17. Cerfolio RJ, Ojha B, Bryant AS, Raghuveer V, Mountz JM, Bartolucci AA. The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. Ann Thorac Surg 2004; 78: 1017–23
18. Bryant AS, Cerfolio RJ, Klemm KM, Ojha B. Maximum standard uptake value of mediastinal lymph nodes on integrated FDG-PET-CT predicts pathology in patients with non-small cell lung cancer. Ann Thorac Surg 2006; 82: 413–22.
19. Nambu A, Kato S, Sato Y et al. Relationship between maximum standardized uptake value (SUVmax) of lung cancer and lymph node metastasis on FDG-PET. Ann Nucl Med 2009; 23: 269–75.
20. Клинические возможности позитронно-эмиссионной томографии: монография/Н.А. Огнерубов, Т. С. Антипова. — Воронеж: Издательскополиграфический центр «Научная книга», 2018. — 117 с.
Review
For citations:
Ognerubov N.A., Antipova T.S. Mediastinal Lymphadenopathy in Non-small Cell Lung Cancer: Prognostic Value of PET/CT. Medical alphabet. 2019;2(17):23-26. (In Russ.) https://doi.org/10.33667/2078-5631-2019-2-17(392)-23-26
Views:
29659
Email this article 